	Les Charges D'Exploitation		Date
Acadia Pharmaceuticals	USD 242.88M	10.68M	2025-09
Akebia Therapeutics	USD 43.82M	16.98M	2025-03
ALKERMES	USD 1.73B	1.44B	2025-09
Alnylam Pharmaceuticals	USD 965.32M	84.27M	2025-12
Amarin	USD 51.37M	14.6M	2025-09
ANI Pharmaceuticals	USD 505.82M	309.62M	2025-09
BioMarin Pharmaceutical	USD 807.82M	259.3M	2025-09
Coherus Biosciences	USD 53.03M	43.41M	2025-03
Emergent BioSolutions	USD 555.9M	242.7M	2023-06
Exact Sciences	USD 875.74M	62.51M	2025-09
Exelixis	USD 362.75M	21.35M	2025-12
Glaxosmithkline	GBP 7.77B	2.22B	2025-09
Heron Therapeutics	USD 38.47M	4M	2024-09
Ionis Pharmaceuticals	USD 316.9M	4.69M	2025-09
Ironwood Pharmaceuticals	USD 57.33M	8.63M	2024-12
Lexicon Pharmaceuticals	USD 57M	10.54M	2024-06
Lonza	CHF 3.09B	564M	2024-12
Merck	USD 10.16B	558M	2025-12
Moderna	USD 1.54B	259M	2025-12
Myriad Genetics	USD 229M	3.4M	2025-09
Nektar Therapeutics	USD 85.09M	109.3M	2025-09
Neurocrine Biosciences	USD 577.6M	22M	2025-12
Pacira	USD 166.36M	4.5M	2025-09
Pfizer	USD 12.91B	79.89B	2025-12
PTC Therapeutics	USD 207.52M	6.21M	2025-09
Sanofi	EUR 10.51B	1.21B	2025-12
Sarepta Therapeutics	USD 462.23M	33.28M	2025-09
United Therapeutics	USD 6.59B	6.07B	2025-09
Vanda Pharmaceuticals	USD 466M	20.33M	2025-09
Xoma	USD 22.84M	1.67M	2024-09

Emergent BioSolutions Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.